Abbvie

A pharmaceutical company that discovers, develops, and markets

Summary

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

 

History

On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The new Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer. The separation was effective January 1, 2013, and AbbVie was officially listed on the New York Stock Exchange (ABBV) on January 2, 2013.

According to Miles White, CEO at the time, the purpose of the split was to allow markets to value the two businesses separately; White said that investors would “benefit from two fundamentally different investment opportunities with distinct strategic profiles and business priorities.” Some investors were concerned that the split was done to protect the value of the device business from the loss of value facing the drug division due to the imminent expiration of patents on Humira, which accounted for about half of the drug division’s revenue.

As of December 2015, the company employed in excess of 28,000 globally, and provided products to individuals in more than 170 countries.

In March 2020, as the COVID-19 pandemic developed into an international crisis, the Israeli government announced that it would force AbbVie to license its patents for Kaletra, the brand name of lopinavir/ritonavir, a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting COVID-19. In response, AbbVie announced that it would cease enforcing its patents on the drug entirely.

Vision

Vision Statement: “Innovative medicines provide compelling patient benefits, differentiated clinical performance, and economic value. We plan to launch 20 new products or indications by 2020 that elevate the standard of care and address significant unmet needs.”

Mission

Mission Statement: “Our Mission Hasn’t Wavered, We’re focused on sustainable growth and addressing the world’s pressing health challenges. We achieve that by developing a consistent stream of innovative new medicines.”

Team

CEO – Richard Gonzalez: Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 47,000 people worldwide and markets medicines in more than 175 countries.

Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada.

References

https://www.facebook.com/AbbVieGlobal/

https://www.linkedin.com/in/richardgonzalezabbvie/

https://en.wikipedia.org/wiki/AbbVie

https://www.comparably.com/companies/abbvie/mission

https://www.crunchbase.com/organization/abbvie

https://www.forbes.com/companies/abbvie/